Brokers Offer Predictions for COGT Q2 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2025 EPS estimates for Cogent Biosciences in a research report issued on Monday, June 30th. Lifesci Capital analyst S. Slutsky forecasts that the technology company will post earnings of ($0.63) per share for the quarter. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Lifesci Capital also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.21) EPS.

Several other equities analysts have also recently issued reports on COGT. Wedbush reiterated a "neutral" rating and set a $10.00 target price on shares of Cogent Biosciences in a research report on Monday. Scotiabank initiated coverage on Cogent Biosciences in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 target price on the stock. HC Wainwright dropped their price target on Cogent Biosciences from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 20th. Piper Sandler raised Cogent Biosciences to a "strong-buy" rating in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cogent Biosciences from $21.00 to $25.00 and gave the company an "overweight" rating in a research report on Thursday, May 29th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $14.43.

Cogent Biosciences Stock Performance

Cogent Biosciences stock traded up $0.21 during mid-day trading on Tuesday, reaching $7.62. 1,862,978 shares of the company were exchanged, compared to its average volume of 1,345,019. The firm's 50-day simple moving average is $6.04 and its two-hundred day simple moving average is $6.75. Cogent Biosciences has a twelve month low of $3.72 and a twelve month high of $12.61. The firm has a market cap of $867.04 million, a PE ratio of -4.14 and a beta of 1.88.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04.

Institutional Trading of Cogent Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in Cogent Biosciences by 84.3% in the fourth quarter. Janus Henderson Group PLC now owns 29,073 shares of the technology company's stock worth $227,000 after purchasing an additional 13,300 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Cogent Biosciences by 78.6% during the fourth quarter. Ameriprise Financial Inc. now owns 21,499 shares of the technology company's stock valued at $168,000 after acquiring an additional 9,459 shares during the period. ProShare Advisors LLC boosted its stake in Cogent Biosciences by 30.5% during the 4th quarter. ProShare Advisors LLC now owns 31,074 shares of the technology company's stock valued at $242,000 after purchasing an additional 7,267 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Cogent Biosciences by 15.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,604 shares of the technology company's stock valued at $1,058,000 after purchasing an additional 17,741 shares during the period. Finally, New York State Common Retirement Fund increased its stake in shares of Cogent Biosciences by 10.5% in the fourth quarter. New York State Common Retirement Fund now owns 23,102 shares of the technology company's stock valued at $180,000 after purchasing an additional 2,200 shares during the period.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.